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ABSTRACT
The erbAa gene encodes two a-thyroid hormone
receptor isoforms, TRa1 and TRo.2, which arise from
alternatively processed mRNAs, erbAa1 (0.1) and erb 0.2
(0.2). The splicing and alternative polyadenylation
patterns of these mRNAs resemble that of mRNAs
encoding different forms of immunoglobulin heavy
chains, which are regulated at the level of alternative
processing during B cell differentiation. This study
examines the levels of erbAa mRNA in eight B cell lines
representing four stages of differentiation in order to
determine whether regulation of the alternatively
processed 0.1 and 0.2 mRNAs parallels the processing
of immunoglobulin heavy chain mRNAs. Results show
that the pattern of 0.1 and 0.2 mRNA expression is
clearly different from that observed for immunoglobulin
heavy chain mRNAs. B cell lines display characteristic
ratios of 0.1/0.2 mRNA at distinct stages of differentiation.
Furthermore, expression of an overlapping gene,
Rev-ErbAa (RevErb), was found to correlate strongly
with an increase in the ratio of 0.1/0.2 mRNA. These
results suggest that alternative processing of erbAa
mRNAs is regulated by a mechanism which is distinct
from that regulating immunoglobulin mRNA. The
correlation between RevErb and erbAa mRNA is
consistent with negative regulation of 0.2 via antisense
interactions with the complementary RevErb mRNA.
INTRODUCTION
Thyroid hormone receptors (TRs) mediate the cellular response
to thyroid hormone (T3) by regulating target gene transcription
(1-3). In all vertebrates TRs are the products of two different
genes, erbAa and erbA~ (4). The mammalian erbAa gene
produces two mRNAs, erbAal (0.1) and erbAa2 (0.2), through

alternative processing of the 3'-end of its pre-~A transcript
(5- 7). These mRNAs give rise to receptor isoforms with
antagonistic functions. 0.1 codes for the a .:thyroid hormone
receptor (TRal), whereas 0.2 codes for an orphan nuclear
receptor (TRa2) which does not bind T3 (6,7). TRa2 competes
with TRal and TR~ for specific DNA binding sites, thereby
antagonizing T3 action (8). Because the erbAa gene produces
both a transcriptional activator (TRal) and its specific inhibitor
(TRa2), regulation of the alternative processing of 0.1 and 0.2
mRNA may provide an important mechanism for determining the
cellular response to thyroid hormone.
Alternative processing of the 3 '-end of erbAa RNA transcripts
involves competition between splicing and polyadenylation.
Polyadenylation at an upstream site yields 0.1 mRNA; whereas
processing from a 5' splice site (ss) within the final exon of 0.1 to
a downstream 3' ss produces 0.2 mRNA. The levels of 0.1 and 0.2
vary in different tissues and at different developmental stages
(9,10). However, the mechanisms which regulate expression of
the alternatively processed mRNAs are not well understood.
Two general models have been described for the regulation of
alternative splicing and polyadenylation (11). In some cases
alternative processing is regulated by transcript-specific factors
which alter the efficiency of either splicing or polyadenylation. hi
other instances, the activity of one or more constitutive components
of the mRNA processing apparatus is altereQ. In the latter case, the
processing of many unrelated transcripts may be affected.
The organization of the erbAa gene and the alternative mRNA
processing of its transcripts appear similar to that of the
immunoglobulin (Ig) heavy chain genes. The Ig heavy chain gene
produces two functionally distinct mRNAs which encode heavy
chains for the membrane-bound (mb) and secreted (sec) forms of
Ig. Like 0.1 , Ig sec mRNA processing utilizes an upstream
polyadenylation site. Similar to 0.2, Ig mb mRNA processing
utilizes a 5' ss in the last common exon to splice to a downstream
exon. Regulation of Ig heavy chain mRNA processi(Jg in B
lymphocytes has been well characterized. In early stages ofB cell
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development downstream splicing ofIg mb mRNA is equal to or
greater than that of Ig sec mRN A processing. At later stages
upstream polyadenylation of Ig sec mRNA predominates (12).
Several studies suggest that the balance between splicing and
polyadenylation required for processing ofIg mb and sec mRNAs
is regulated by a change in the level of a general polyadenylation
factor (13-1 6). In view of these findings, it is possible that erbAa.
mRNA processing may parallel that of Ig heavy chain mRNA
during B cell development.
A distinguishing feature of the mammalian erbAa. gene locus
is the presence of a third gene, Rev-ErbAa. (RevErb), encoded on
the DNA strand opposite erbAa. (17,18). The 3' exon of RevErb
overlaps with the a.2-specific 3' exon but not with 0.1 sequence.
The unusual organization of these genes results in 0.2 and RevErb
mRNAs which are complementary at their 3'-ends allowing the
possible formation of antisense/sense RNA duplexes. Such
basepairing interactions between the RevErb and 0.2 mRNAs
could negatively regulate a.2 mRNA levels, and therefore offer a
transcript-specific mechanism by which 0.1 and a.2 mRNA levels
are regulated.
In this study, we examine the expression of 0.1 and 0.2 mRNA
from B cells representing different stages of differentiation. We
find that the thyroid hormone receptor, TRa.l , and the orphan
receptors TRa.2 and RevErb are expressed at all stages of
differentiation but at varying levels in the different cell lines. Our
results indicate that the regulation of alternative RNA processing
of 0.1 and a.2 is distinct from that ofIg sec and mb RNA processing .
regulation. However, changes in the relative levels of 0.1 and a.2
correlate strongly with variations in levels of RevErb mRNA.
MATERIALS AND METHODS

Cell lines
All cell lines are from the mouse B cell lineage and were grown
as previously described (13,14,19,20). 70Z/3.12 represents a
pre-B cell stage line with equal amounts of sec and mb IgM
mRNA (20). WEHI-231 is an early B cell with equal amounts of
sec and mb IgM (20). The M12 cell line represents an early B cell
which has lost its endogenous heavy chain but expresses
approximately equal amounts of sec and mb IgM mRNA when
transfected with an IgM gene (13). The A20 and 2PK3 cell lines
are memory B cells and produce about equal quantities of sec and
mb IgG heavy chain mRNA (14). 4TOOI is a plasmacytoma cell
line which secretes large amounts ofy2b, K molecules ofIgG (14).
S 194 is a plasmacytoma cell line which has lost its endogenous
heavy chain but produces a large excess of sec over mb mRNA
when transfected with an IgM gene (J 3). J558L is a plasmacytoma cell line which has lost its endogenous a. heavy chain but
when transfected with an IgG gene sec mRNA is expressed in
excess over mb mRNA (19).
Recombinant plasmids and RNA probes
The erbAa. probe used for northern analysis was prepared from
a 600 ntXbaI-SacI DNA fragment excised from plasmid pa.2HN.
pa.2HN contains an EcoRI- HincII fragment which is common to
both 0.1 and 0.2. This fragment was isolated from plasmid
pa.2t1C-Sac/stop (21) and subcloned in pBluescript KS+
(Stratagene). The probe was uniformly labeled with [a._ 32pjdCTP
by random oligonucleotide-primed synthesis (22). For RNase
protection assays, a single-stranded antisense riboprobe ofa.l and
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0.2 common sequence was prepared from pB3EOP which
contains the 162 ntPstI- EcoOl091 erbAa. DNA fragment cloned
between the ApaI-PstI sites ofpBluescript KS+. This fragment of
the erbAa. gene spans the a.2-specific 5' ss within the 3'-most
exon of 0.1. pB3EOP was linearized with XbaI and transcribed
with T3 RNA polymerase to produce a 209 nt probe. Of this
probe, 162 nt are complementary to 0.1 mRNA and 135 nt are
complementary to a.2 mRNA. The RevErb riboprobe was made
from pB4E6 which contains 303 nt of a Bgm- Bsu361 fragment
from pB4-1 (17) cloned into pBluescript KS+. pB4E6 was
linearized withXbaI and transcribed with T3 RNA polymerase to
produce a 360 nt probe, 130 nt of which are complementary to
RevErb exon 6. RNA probes were uniformly labeled with
[a._ 32pjUTP and purified by electrophoresis (22). Plasmids
pa.2t1C-Sac/stop and pB4-1 were generously provided by M.A.
Lazar, University of Pennsylvania.
RNA isolation and northern analysis
Cytoplasmic RNAs were isolated by detergent lysis and phenoV
chloroform extraction as previously described (19). The RNA was
passed over oligo(dT) columns to isolate poly(At RNA.
Electphoresis of 1-3 Ilg of poly(At RNA on a
1.0% agarose-D.22 M formaldehyde ' gel was run in buffer
containing 0.22 M formaldehyde. The RNA was transferred 'by
capillary action to Nytran (Schleicher and Schuell, Inc.) after
which the RNA was UV-irradiated and hybridized to labeled
probes (23). RNA size markers (GIBCO-BRL) were included on
the gel and stained with methylene blue after transfer to Nytran
(22).
RNase protection assays
Labeled probes were hybridized to 10-30 Ilg target RNAs as
previously described (22). The resulting hybrids were digested
with 1.5 III RNase (1 mg/ml RNase A, 20 000 U/ml RNase Tl,
Ambion, Inc.) at 30°C for 1 hr. Protected RNAs were denatured
in formamide and resolved on 5.5% polyacrylamide- urea gels.
Band intensities were quantified by radioanalytic scanning with
an AMBIS 100 Image Analyzer. Background was subtracted by
using regions of identical size located immediately above each
experimental band. RevErb/a.2 ratios were computed from
experiments in which probes were prepared in parallel using
identical mixes of labeled and unlabeled nucleotides to ensure
identical specific activities. The specific activity of the probes
ranged from 9 x 108 to 2 x 109 c.p.m.lnmol between experiments.
Molar ratios were calculated after correcting for length and
composition of the protected RNA fragments.
RESULTS

Structural organization and expression of erbAa.
mRNAs in B cell lines
In mammals, a single locus codes for the two alternatively
processed erbAa. mRNAs and the overlapping RevErb mRNA
(Fig. IA). To determine if the erbAa.mRNAs are expressed in B
lymphocytes, we assayed 0.1 and a.2 mRNA levels in two mouse
B cell lines representing different stages of differentiation. The
cell line 70Zl3 is a tumor line arrested in the pre-B cell stage (20)
and J558L is a myeloma cell line representing a late-stage B cell
or plasma cell line (19). The C6 rat astrocytoma cell line, which
is well-characterized for erbAa. mRNA levels (9), was also
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Figure 1. Expression of erbAa and RevErb in B cell lines. (A) Structural
organization of the overlapping c-erbAo. locus. Arrows indicate the direction
of transcription, boxes represent exons, lines represent introns. Shaded boxes

represent 5' and 3' untranslated regions. Vertical, dotted lines demarcate
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RevErb and CL2 complementary sequence. The ai , CL2 and RevErb poly(A) sites
are noted. The alternative splicing of the a1-specific exon is represented by the

angled line above the map. Probes used in RNase protection assays are
indicated as bars beneath the sequence with length of the protected fragments
indicated in nt. (8) Northern blot analysis of I ~g 70Z13 (lane I), 2 ~g J558L
(lane 2) and 3 ~g C6 (lane 3) polyA+ cytoplasmic RNA. Blots were hybridized
with a probe from the region common to al and CL2.

analyzed. Northern blot experiments using an erbAa specific
probe show the expected 5.5 kb al mRNA and 2.6 kb a2 mRNA
which correspond to the documented sizes of C6 cell a I and a2
mRNA (Fig. I B) (J 7). These results demonstrate that both erbAa
mRN As are expressed at early and late stages of B cell
differentiation.

Alternative mRNA processing of erbAa mRNA
We next asked whether the balance between alternative processing ofal and a2 mRNA parallels that ofIg sec and mb mRNA
at different stages of B cell differentiation. Cytoplasmic mRNA
was analyzed from eight mouse cell lines representing four
different stages of B cell development. In addition to the pre-B
and plasmacytoma cell lines described above, mRNA from two
mature B cell lines [WEHI-231 (20) and MI2 (13)], two cell lines
representing memory B cells [2PK3 and A20 (14)], and two
additional plasma cell lines [4TOOI (14) and SI94 (13)] were
examined to determine the levels of expression of a 1 and a2
mRNA. RNase protection assays of mRNA from these eight cell
lines show that the pre-B cell line, 70Zl3, has the highest ratio of
alla2 mRNA, 3.6, indicating a predominance of upstream
polyadenylation over downstream splicing (Fig. 2A and B). The
lowest alla2 ratios are seen in the plasma cell lines, SI94 and
J558L and the mature B cell line, M 12, which demonstrates an
excess of a2 splicing over polyadenylation. The ratios of alla2
mRNA in the different B cell lines are clearly distinct from those

Figure 2. Differential erbAa alternative RNA processing in 8 cell lines
representing various stages of differentiation. (A) RNase protection assays of
B cell cytoplasmic mRNA using the erbAa and RevErb-specific probes shown
in Figure I A. Assays were carried out with I 0 ~g J558L RNA, 20 ~g 70Z13,
M12, 4TOOI , S 194 RNA and 30 ~g WEHI-23I, 2PK3, A20 RNA. Assays were
carried out in parallel except for those shown in lanes 3 and 7 which were
analyzed in a separa1e experiment. Lanes 9 and 10 show results of the same
experiment in lanes 4 and 5 except for a 2-fold increase in exposure time. The
specific B cell lines and their representative stage in differentiation is indicated
above each lane. The protected fragments corresponding to a I, a2 and RevErb
mRNAs are indicated at left. (8) Comparison of the ratio ofallCL2 mRNA and
Ig sec/mb mRNAs (13, 14, 19,20) is shown schematically.

seen for sec and mb mRNA from the Ig heavy chain gene
(Fig. 2B). For example, the levels of Ig sec (polyadenylated)
mRNA levels are nearly equal to those ofig mb (spliced) mRNA
at early stages ofB cell differentiation but increase sharply as cells
switch almost exclusively to production of Ig sec mRNA in
plasma cells. Although changes in the levels of erbAa mRNAs
during B cell differentiation are opposite from the Ig mRNA
alternative processing pattern, B cell lines representing distinct
developmental stages display characteristic ratios of al/a2
mRNA (Fig. 2B, Table I).

Expression of RevErbAa mRNA in B cells
The complementary, overlapping organization of the erbAa and
RevErb genes may have important implications for the coordinate
regulation of these genes. To determine whether the differential
expression of erbAa RNA processing during B cell differentiation correlates with changes in expression of RevErb, we
assessed the levels of RevErb mRNA in parallel with al and a2
mRNA in the same eight B cell lines. RevErb mRNA is expressed
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in all of the cell lines but at variable levels (Fig. 2A). The highest
expression of RevErb is seen in the 70Zl3 mRNA, which shows
an 8-fo ld excess of RevErb over a2. Conversely, S 194, J558L and
MI2 mRNA, the cell lines with the lowest al /a2 (1.0-0.8), also
have the lowest RevErb/a2 ratio (0.5-0.9) though their absolute
levels of RevErb extend over a broad range. In general, increases
in the ratio ofRevErb/a2 correlate strongly with increases in the
ratio ofalla2 (Fig. 3, Table 1).
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B lymphocyte cell lines provide a unique system for investigating
the molecular basis of developmentally regulated alternative
processing. Such processing has been intensively studied for Ig
heavy chain genes during B cell differentiation. In this study we
show that erbAa mRNAs are expressed at different levels in
B cell lines representing specific stages of development. The ratio
ofalla2 mRNA varies in a manner which suggests stage-specific
regulation of mRNA levels, but the pattern of expression is
clearly different from the variations in sec/mb mRNA levels.
Characterization ofmRNA levels from the overlapping RevErb
gene shows that expression of RevErb mRNA correlates with
changes in the alla2 ratio. These observations have important
implications both for regulation of alternative processing and for
the role of thyroid hormone during B cell development.
Molecular analysis of Ig heavy chain mRNA processing has
shown that regulation of polyadenylation and splicing depends on
changes in the levels of essential processing factors (14,16). Of
particular interest to this study is the observation that unrelated
pre-mRNAs which undergo similar 3'-end processing are differentially processed throughout B cell differentiation in the same
manner as Ig sec and mb heavy chain mRNAs (13,15). On the
basis of these results, erbAa mRNA processing would also be
predicted to parallel that of Ig heavy chain mRNAs, with the
alla2 ratio lowest in pre-B cells, highest in plasmacytoma cells
and at intermediate levels in mature and memory B cells. Our
results show a different and more complex pattern of variation in
the alla2 expression than predicted. Mature B cells and plasma
cells both have relatively low alla2 ratios whi le higher ratios are
observed for memory cells and the pre-B cell line. These results
suggest that the balance between alternative splicing and

o~--~

____

0.1

~

__

~~--~--~~~~

1
Rev-Erb/a2

Figure 3. RevErb mRNA expression in B cell lines related to changes in
alla2 mRNA. The ratio ofRevErb/a2 mRNA was quantified and compared
to al /a2 mRNA. Data is presented in a scatter plot with each point
representing a specific cell line. The representative developmental stage for
each cell line is indicated by specific symbols.

polyadenylation of erbAa mRNAs is regulated in a manner
independent of Ig heavy chain alternative mRNA processing.
One possible mechanism for regulating expression of erbAa
mRNAs involves interactions with the RevErb mRNA. Since this
overlapping mRNA is complementary to 02, but not ai,
variations in RevErb expression may differentially affect al and
a2 expression. The results presented here are consistent with such
a relationship. Despite wide variations in the levels at which these
mRNAs are expressed in the eight lymphocyte cell lines analyzed
(Table I), a strong correlation is evident between the ratio of
RevErb/a2 and the ratio of alla2 (Fig. 3). Specifically, when the
ratio ofRevErb/a2 is between 0.4 and 1.2, the a 1102 ratio is <1.5,
and when the RevErb/a2 is >2.0 the alla2 ratio is ~2.5. Thus, an
increase from 1.5 to 2.0 in the RevErb/a2 ratio may represent a
threshold associated with a 2- to 3-fold increase in alla2. Since
the ratio ofRevErb/a2 varies over a wider range than the ratio of
alla2 and there is no evident correlation in the variation of
RevErb and a2 levels, interactions between these genes or their
mRNA products may be modulated by additional factors.

Table I. Quantitation of ai , a2 and RevErb mRNA in B cell lines
amol/~g

alla2 (S.D.)

RevErb/a2 (S.D.)

12.9

3.6 (0.3)

7.9 (0.4)

0.65

1.3 (0.2)

1.0 (0.3)

1.4

0.S2 (0.1 6)

0.46 (0.04)

0.22

0.5

3.3 (1.0)

2.4 (0.4)
2.0

112 amol/~g

Cell line

al

70Zl3

5.5

1.7

WEHI -23 I

0.9

0.75

MI2

2.3

3.2

2PIG

0.S5

RevErb

10

amol/~g

A20

0.6

0.3

0.5

2.5

4TOOI

2.4

1.6

I. S

1.5 (0.0)

1.2 (0.5)

SI94

2.9

3.1

2.S

1.0 (0.2)

0.91 (0.00)

J55SL

S. I

9.6

5.3

0.94 (0. 12)

0.63 (O.I S)

Levels of erbAa and RevErb mRNAs detennined by RNase protection assays as shown in Figure 2. A quantitative detennination of the al and
112 mRNA levels in each of the cell lines was obtained after correction for mRNA loading and specific activity of the protected fragments . The
abundance of both erbAa mRNA s is - 0.1 % that ofmRNA from the housekeeping gene GAPDH (data not shown). Ratios of alla2 mRNA represent the average of three or four experiments. Data from the A20 cell line represents a single experiment. Absolute values and RevErb/a2 ratios
are the average of two experiments carried out in parallel with probes of identical specific activity.
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The relationship between RevErb expression and erbAa
mRNA processing, described above, may reflect either direct or
indirect interactions between these genes or their products.
Several other studies have suggested that increased expression of
RevErb mRNA may result in a decrease in a2 mRNA relative to
al (24--26). Cycloheximide treatment of a particular pituitary
tumor cell line results in a coordinate increase in both RevErb and
the a1la2 ratio (24). Similarly, when adipocyte cells are induced
to differentiate in vitro, an increase in RevErb mRNA and the
a lIa2 ratio is observed (25). The increase in a1la2 observed in
both these studies clearly reflects alterations in the processing of
erbAa pre-mRNA, since neither the rate of transcription nor the
relative stability of al and a2 are altered (24,25). However, it
should be noted that in both cases the treatments used cause
multiple, widespread alterations in cellular metabolism, in
addition to altering levels of RevErb and erbAa mRNA.
In a third study antisense RNA corresponding to the overlapping
portion of RevErb mRNA was shown to efficiently block splicing
of erbAa pre-mRNA in vitro (26). In this case the increasing levels
of the antisense RNA clearly block mRNA splicing. However, the
relevance of this in vitro system as a model for physiological
regulation is not clear. Antisense regulation at the level of
alternative mRNA processing may provide a novel mechanism for
the regulation of functionally antagonistic nuclear receptors.
Although artificial antisense transcripts and oligonucleotides have
been employed to repress expression of many genes, naturally
occurring antisense regulation has not been well characterized in
higher eukaryotes (27-29). The clear correlation between RevErb
expression and al /a2 mRNA levels described here for eight
lymphocyte cell lines, and the results of previous studies (24--26),
support a direct role for RevErb in the regulation of relative levels
of erbAa mRNAs. Rigorous demonstration of a physiologically
relevant antisense mechanism will require evidence that base-pairing interactions between a2 and RevErb transcripts are essential
for the negative regulation of a2-specific splicing in vivo.
The differential expression of al and a2 mRNAs may have
important physiological consequences for B cell differentiation.
However, little is known regarding the role of the receptor protein
during lymphocyte regulation. This study is the first to report the
expression of mRNAs for specific TRs in B cells. Earlier studies
have shown that T3 stimulates B cell proliferation and differentiation (30,31), which appears to be a result of changes in T3
reception during differentiation (32). One specific role for TRs in
B cell differentiation may involve direct interactions of TRs with
the transcription factor AP-I, which regulates stage-specific
functions required for B cell proliferation and differentiation (33).
The activity of AP-I is modulated by a number of agents including
ligand-activated transcription factors which belong to the TR-related subfamily (34). Both TRa and TR~ have been shown to
interfere with AP-I activated transcription in a T3-dependent
manner via direct protein- protein interactions (35,36). Thus, the
activity of AP-I during B cell differentiation may be modulated by
alterations in the levels of TRa 1 and its antagonist, TRa2.
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